The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

Active Grant Awarded

Award ID
R01CA315906
Recipient
Awarding agency
Obligated
$514,864

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 4% complete
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The Methodist Hospital Research Institute $514,864 on September 9, 2026, under the Cancer Biology Research program (CFDA 93.396), an assistance grant rather than a procurement contract. The funded work investigates the role and mechanisms of the GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer, with particular focus on immune evasion. The proposed study examines all three neuroendocrine prostate cancer phenotypes (elevated neuroendocrine marker expression, increased angiogenesis, and immune evasion) across multiple immunocompetent settings, including syngeneic mouse tumors.

The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is Houston, Texas 77030.

The federal program funds fundamental research on the cause and nature of cancer, with the expectation that the findings will improve the prevention, detection, diagnosis, and treatment of neoplastic diseases. The source describes no sub-recipients for this award.

Description

Abstract
/summary prostate cancer (PCA) is a major health concern for men in the united states, ranking as the second- leading cause of cancer-related death. Most PCA initially responds to androgen deprivation therapy, but invariably develop resistance and relapse. A common consequence of resistance to hormonal therapy is the emergence of neuroendocrine prostate cancer (NEPC), an aggressive PCA variant. NEPC is marked by a high proportion of tumor cells positive for neuroendocrine (NE) markers, with an associated patient survival of less than one year. Despite the urgent need for effective NEPC treatments, our limited understanding of its mechanisms and the scarcity of good drug targets pose significant challenges. NEPC exhibits three major phenotypes: elevated NE marker expression, increased angiogenesis, and immune evasion, which are expected to be interconnected. However, the direct molecular links between these phenotypes remain unclear. To identify novel regulators of NEPC, we previously examined 147 epigenetic regulators, and identified HDAC2 (histone deacetylase 2) as one of the most upregulated epigenetic regulators in NEPC. HDAC2 is activated by its novel kinase regulator, GRK3 (gpcr kinase 3), which is also upregulated in NEPC. We have shown that GRK3 and HDAC2 link NE marker expression with angiogenesis, and our new data suggest that the GRK3-HDAC2 axis promotes immune evasion, likely by repressing a group of interferon response-related genes. Thus, this epigenetic pathway may serve as a crucial link between the three NEPC phenotypes. Our recent study only linked NE with angiogenesis, and IT was limited to human cells in immunodeficient xenograft models. We propose to investigate the role and mechanisms of the GRK3-HDAC2 pathway in all three NEPC phenotypes, particularly immune evasion, in multiple immunocompetent settings, including syngeneic mouse tumors (aim 1), genetically engineered mouse models (aim 2), and patient samples (aim 3A). Our findings also suggest that targeting this axis could effectively inhibit NEPC. Through compound library screening, we identified two potent specific GRK3 inhibitors, both of which significantly inhibited NEPC cell growth in culture and in xenografts. One inhibitor was further tested in immunocompetent mice with syngeneic tumors, where IT slowed NEPC tumor growth and enhanced the efficacy of anti-PD-1 immunotherapy. We aim to further test these inhibitors in multiple syngeneic models, both alone and combined with immunotherapy (aim 3B). This project is highly significant and innovative, as IT will, for the first time, connect the three NEPC phenotypes through a single pathway, reveal essential NEPC repressors as novel epigenetic targets of HDAC2, and identify new drug targets and candidates to impede NEPC progression and overcome immunotherapy resistance. We anticipate that this work will substantially impact NEPC understanding and treatment.

Quick answers

Who received award R01CA315906?

R01CA315906 was awarded to The Methodist Hospital Research Institute by National Cancer Institute (National Institutes of Health) on September 9, 2026.

How much is award R01CA315906 worth?

$514,864 has been obligated on R01CA315906.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award